Abstract
The drug discovery pipeline for leishmaniasis and trypanosomiasis has been filling with novel chemical entities with known mechanisms of action. González et al. and Braillard et al. report a cytochrome bc1 complex inhibitor as another promising preclinical candidate for visceral leishmaniasis (VL) and, in combination with benznidazole, for chronic Chagas' disease (CCD).
Original language | English |
---|---|
Pages (from-to) | 211-213 |
Number of pages | 3 |
Journal | Trends in parasitology |
Volume | 40 |
Issue number | 3 |
DOIs | |
Publication status | Published - 6 Mar 2024 |
Bibliographical note
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.Keywords
- Humans
- Chagas Disease/drug therapy
- Leishmaniasis/drug therapy
- Trypanosomiasis
- Leishmaniasis, Visceral/drug therapy
- Trypanosoma cruzi